CYTEK BIOSCIENCES, INC. (CTKB) Spending and interest coverage
- R&D / revenue · 12 months: Value 18.03%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 10.34%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 18.03% | Research and development expense / revenue. Period ending 2026-06-30. $37.26M ÷ $206.71M × 100 ≈ 18.03% |
| Stock-based compensation / revenue · 12 months | 10.34% | Share-based compensation / revenue. Period ending 2026-06-30. $21.36M ÷ $206.71M × 100 ≈ 10.34% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 37.26M USD | Research and Development Expense |
| Revenue | 206.71M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 21.36M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -44.65M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $37.26M | $206.71M | $21.36M | $-44.65M | (m) | 18.03% | 10.34% | (m) | (m) |
| 2026-03-31 | $36.35M | $204.17M | $22.82M | $-43.87M | (m) | 17.80% | 11.17% | (m) | (m) |
| 2025-12-31 | $36.47M | $201.49M | $24.59M | $-40.38M | (m) | 18.10% | 12.20% | (m) | (m) |
| 2025-09-30 | $37.23M | $196.83M | $26.06M | $-31.80M | (m) | 18.91% | 13.24% | (m) | (m) |
| 2025-06-30 | $38.16M | $196.03M | $27.48M | $-26.86M | (m) | 19.46% | 14.02% | (m) | (m) |
| 2025-03-31 | $39.33M | $197.05M | $27.84M | $-24.76M | (m) | 19.96% | 14.13% | (m) | (m) |
| 2024-12-31 | $39.40M | $200.45M | $26.85M | $-20.52M | (m) | 19.66% | 13.39% | (m) | (m) |
| 2024-09-30 | $40.55M | $201.21M | $25.51M | $-23.65M | (m) | 20.15% | 12.68% | (m) | (m) |
| 2024-06-30 | $41.84M | $197.71M | $24.22M | $-25.82M | (m) | 21.16% | 12.25% | (m) | (m) |
| 2024-03-31 | $43.97M | $200.79M | $22.99M | $-26.42M | $1.84M | 21.90% | 11.45% | -14.36× | Reported |
| 2023-12-31 | $44.15M | $193.01M | $22.05M | $-27.84M | $2.07M | 22.87% | 11.42% | -13.45× | Reported |
| 2023-09-30 | $43.03M | $183.12M | $20.84M | $-27.62M | $2.36M | 23.50% | 11.38% | -11.69× | Reported |
| 2023-06-30 | $40.51M | $175.59M | $19.45M | $-19.84M | $2.42M | 23.07% | 11.07% | -8.21× | Reported |
| 2023-03-31 | $36.81M | $166.06M | $17.46M | $-11.61M | $2.66M | 22.16% | 10.51% | -4.37× | Reported |
| 2022-12-31 | $34.86M | $164.04M | $16.59M | $-1.80M | $2.57M | 21.25% | 10.12% | -0.70× | Reported |
| 2022-09-30 | $32.19M | $154.59M | $15.14M | $-571.00K | $2.38M | 20.82% | 9.79% | -0.24× | Reported |
| 2022-06-30 | $29.61M | $148.49M | $13.23M | $10.85M | $2.17M | 19.94% | 8.91% | 5.00× | Reported |
| 2022-03-31 | $27.37M | $138.74M | $9.97M | $5.67M | $1.96M | 19.73% | 7.18% | 2.90× | Reported |
| 2021-12-31 | $24.44M | $127.95M | $6.59M | $9.16M | $1.74M | 19.10% | 5.15% | 5.26× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $13.69M | $92.84M | $611.00K | $13.66M | $333.00K | 14.75% | 0.66% | 41.02× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |